The CSL share price is up 26% in 2019

The CSL Limited (ASX:CSL) share price has been on form again in 2019. Is it too late to invest?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Although it is trading lower today after going ex-dividend, the CSL Limited (ASX: CSL) share price has been in fine form again in 2019.

Since the start of the year the biotherapeutics company's shares have gained a sizeable 26.2%.

This has stretched the company's three-year share price gain to a massive 130%.

Why is the CSL share price up 26% in 2019?

Investors have been scrambling to buy the company's shares again this year after it delivered another strong result in FY 2019.

For the 12 months ended June 30, CSL posted an 11% increase in revenue to US$8,539 million and a 17% jump in net profit after tax to US$1,919 million.

One of the key drivers of this strong growth was its Immunoglobulins product range. Sales of immunoglobulins grew at an above-market rate of 16% to US$3,543 million thanks to a combination of factors including increased usage for chronic therapies, growing awareness and diagnosis, and the expanding usage for secondary immunodeficiency.

This was supported by a 6% lift in Speciality sales due to high patient demand for its Haegarda and Kcentra products and a 15% jump in Albumin sales thanks to strong growth in China in the second half.

This ultimately led to the key CSL Behring business reporting an 11% increase in total revenue to US$7,343 million during the 12 months.

The market will no doubt have been impressed with the performance of its fledgling Seqirus influenza vaccine business. The Seqirus business posted a 12% increase in total revenue to US$1,196 million due to strong demand for its seasonal influenza vaccines.

Outlook positive.

Also supporting its strong share price gain this year has been management's guidance for the year ahead.

Despite the one-off headwinds associated with its transition to a self-distribution model in China, management is confident of solid profit growth in FY 2020.

It has provided revenue growth guidance of 6% and net profit after tax growth guidance of 7% to 10% in constant currency term in FY 2020.

Should you invest?

Whilst its shares look reasonably expensive after this strong gain, I believe this premium is justified due to the quality of the company and its strong long-term growth potential thanks to increasing demand and its lucrative development pipeline.

Overall, I continue to class its shares as a great buy and hold option along with fellow healthcare stars Cochlear Limited (ASX: COH) and ResMed Inc. (ASX: RMD).

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ⏸️ ASX Shares

a woman wearing a close-sitting hat featuring wires and thick computer screen glasses clutches her computer monitor and looks shocked and disturbed as she reads old-fashioned computer text from the screen.
Technology Shares

Here's why ASX 200 tech shares (ASX:XTX) outperformed today

ASX tech shares have taken a turn for the better today.

Read more »

Worker in hard hat looks puzzled with one hand on chin
Resources Shares

Why did the Rio Tinto share price (ASX:RIO) have such a lousy 2021?

We look at what happened to this ASX 200 mining giant's shares last year

Read more »

a miner wearing a hard hat smiles as he stands in front of heavy earth moving equipment on a barren mine site.
Share Gainers

Here's why the Rumble Resources (ASX:RTR) share price is climbing 5%

The mineral explorer's share price is on the rise amid promising drill results.

Read more »

share price high, all time record, record share price, highest, price rise, increase, up,
⏸️ ASX Shares

Here are the top 10 ASX 200 shares on Wednesday

Here are your top 10 biggest gainers in the ASX 200 on Wednesday.

Read more »

comical investor reading documents and surrounded by calculators
⏸️ ASX Shares

The ASX reporting wrap-up: WiseTech, Bravura, Seven Group

Just what the investor ordered. Here’s a recap of the companies that reported on Wednesday...

Read more »

Doctor performing an ultrasound on pregnant woman
⏸️ ASX Shares

The ASX reporting wrap-up: Ansell, Kogan, Nanosonics

Just what the investor ordered. Here’s a recap of the companies that reported on Tuesday...

Read more »

blue arrows representing a rising share price ASX 200
⏸️ ASX Shares

Here are the top 10 ASX 200 shares on Tuesday

Here are your top 10 biggest gainers in the ASX 200 on Tuesday.

Read more »

unhappy investor considering computer screen
Share Market News

The ASX reporting wrap-up: Charter Hall, Ampol, NIB Holdings

Just what the investor ordered. Here’s a recap of the companies that reported on Monday...

Read more »